
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. is positioned positively due to its proprietary product candidate, lorundrostat, which has shown the ability to deliver a substantial placebo-adjusted blood pressure (BP) benefit exceeding 10 mmHg in patients with uncontrolled and resistant hypertension. The company benefits from a differentiated therapeutic profile that stands out against competitors, particularly highlighted by recent discussions with key opinion leaders (KOLs) regarding favorable Phase 3 data. Additionally, there is optimism surrounding an imminent FDA feedback and anticipated New Drug Application (NDA) submission, which could further bolster the company's growth prospects.
Bears say
Mineralys Therapeutics faces significant challenges that negatively impact its stock outlook, primarily due to uncertainties surrounding the market potential of its product candidate, lorundrostat, which may not achieve projected peak commercial revenues due to factors like market size and pricing strategies. Furthermore, the company could struggle to secure the necessary capital resources to sustain its operations, jeopardizing future developmental and commercialization efforts. The potential for increased observed hyperkalemia levels, as highlighted by key opinion leaders, raises additional concerns regarding the drug's safety profile, which may further hinder its market acceptance and financial viability.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares